Resectable research hub

Durvalumab (MEDI4736 ) plus tremelimumab in resectable, locally advanced squamous cell carcinoma of the oral cavity: a window of opportunity study

This study looks at new drug combinations before surgery for a type of mouth cancer. Researchers want to see if these drugs can boost the body's immune response inside the cancer. It's an early-stage study to understand if these treatments could be helpful and safe for patients.